Feasibility of Measuring Gene Expression Patterns Using Tissue Acquisition of Primary Stage 3 & 4 Epithelial Ovarian Cx or Primary Peritoneal Cx & Gene Expression Array Technology for Predicting Paclitaxel Chemotherapy
- Identify genetic markers of paclitaxel chemosensitivity and/or chemoresistance, using
gene expression arrays, in patients with newly diagnosed stage III or IV ovarian
epithelial cancer or primary peritoneal cancer treated with single-agent weekly
paclitaxel followed by paclitaxel in combination with carboplatin.
- Correlate RNA expression levels with clinical response in patients treated with this
- Determine the response rate in patients treated with this regimen.
- Determine the progression-free survival and overall survival of patients treated with
- Compare transcriptional profiles of primary tumors vs tissue obtained at second-look
surgery in patients treated with this regimen.
- Identify differential expression between pre- and post-treatment tissue in patients
treated with this regimen.
OUTLINE: This is a pilot study.
Pre- and post-chemotherapy tumor samples undergo transcriptional profiling using cDNA
microarrays to identify gene overexpression. The gene expression profiles of
paclitaxel-sensitive tumors are compared with those that are paclitaxel resistant to
identify gene markers that are associated with response to paclitaxel.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Observational Model: Case-Only, Time Perspective: Prospective
Genetic markers of paclitaxel chemosensitivity and/or chemoresistance
David M. Gershenson, MD
M.D. Anderson Cancer Center
United States: Federal Government
|UT MD Anderson Cancer Center||Houston, Texas 77030|